GLP1R and myocardial infarction: In SUSTAIN 6, in addition to significantly reducing the risk of the primary outcome (3-point MACE: CV death, non-fatal stroke, non-fatal myocardial infarction), s.c. semaglutide significantly decreased the incidence of new or worsening nephropathy and of non-fatal stroke vs placebo [13]—the latter being a finding that has not been observed in CVOTs with other GLP-1 receptor agonists [43].